JNK-IN-8 - CAS# 1410880-22-6 Catalog No.:M6416-10 IRE-3 inhibits the XBP1 mRNA

IRE-3 inhibits the XBP1 mRNA splicing through binding to the IRE1α ATP-binding site

thus attenuating phosphorylation of the Aurora substrate H3S10

indicating that cycling populations of normal cells induce Chk1 pS345 following exposure to MK-8776 S-isomer as part of a futile cycle

LY2109761 treatment at 1 nM is sufficient to significantly block the migration and invasion but not adhesion of hepatocellular carcinoma cells by increasing E-cadherin expression

IC50 value: Target: cathepsin K The cathepsin K inhibitor AAE-581 (balicatib) as the most advanced of them passed Phase II clinical trials in 2005

JNK-IN-8 - CAS# 1410880-22-6 Catalog No.:M6416-10 IRE-3 inhibits the XBP1 mRNAJNK IN 8, also known as JNK Inhibitor XVI, CAS No. 1410880 22 6, is a selective JNK inhibitor that inhibits phosphorylation of c Jun, a direct substrate of JNK, in cells exposed to submicromolar drug in a manner that depends on covalent modification of the conserved cysteine residue. Extensive biochemical, cellular, and pathway based profiling establish the selectivity of JNK IN 8 for JNK and suggests that the compound will be broadly useful as a